Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | perforin-like protein 3 | 0.0055 | 0.3362 | 0.5 |
Toxoplasma gondii | MAC/Perforin domain-containing protein | 0.0055 | 0.3362 | 0.5 |
Plasmodium falciparum | perforin-like protein 4 | 0.0055 | 0.3362 | 0.5 |
Plasmodium vivax | perforin-like protein 5 | 0.0055 | 0.3362 | 0.5 |
Plasmodium falciparum | perforin-like protein 1 | 0.0055 | 0.3362 | 0.5 |
Echinococcus granulosus | macrophage expressed protein | 0.0055 | 0.3362 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0055 | 0.3362 | 0.7669 |
Plasmodium vivax | perforin-like protein 3 | 0.0055 | 0.3362 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.006 | 0.4384 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.4384 | 0.4384 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0087 | 1 | 1 |
Echinococcus multilocularis | macrophage expressed protein | 0.0055 | 0.3362 | 1 |
Plasmodium vivax | perforin-like protein 1 | 0.0055 | 0.3362 | 0.5 |
Plasmodium vivax | perforin-like protein 2 | 0.0055 | 0.3362 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0087 | 1 | 1 |
Plasmodium falciparum | perforin-like protein 5 | 0.0055 | 0.3362 | 0.5 |
Chlamydia trachomatis | hypothetical protein | 0.0055 | 0.3362 | 0.5 |
Toxoplasma gondii | perforin-like protein PLP1 | 0.0055 | 0.3362 | 0.5 |
Plasmodium falciparum | perforin-like protein 2 | 0.0055 | 0.3362 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.006 | 0.4384 | 0.4384 |
Plasmodium vivax | perforin-like protein 4 | 0.0055 | 0.3362 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.